AU2017286368B2 - Heterocyclic compounds as antibacterials - Google Patents

Heterocyclic compounds as antibacterials Download PDF

Info

Publication number
AU2017286368B2
AU2017286368B2 AU2017286368A AU2017286368A AU2017286368B2 AU 2017286368 B2 AU2017286368 B2 AU 2017286368B2 AU 2017286368 A AU2017286368 A AU 2017286368A AU 2017286368 A AU2017286368 A AU 2017286368A AU 2017286368 B2 AU2017286368 B2 AU 2017286368B2
Authority
AU
Australia
Prior art keywords
sub
ring
compound
alkyl
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017286368A
Other languages
English (en)
Other versions
AU2017286368A1 (en
Inventor
Jérôme Émile Georges GUILLEMONT
Pierre Jean-Marie Bernard Raboisson
Abdellah Tahri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2017286368A1 publication Critical patent/AU2017286368A1/en
Application granted granted Critical
Publication of AU2017286368B2 publication Critical patent/AU2017286368B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017286368A 2016-06-16 2017-06-15 Heterocyclic compounds as antibacterials Ceased AU2017286368B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174719 2016-06-16
EP16174719.1 2016-06-16
PCT/EP2017/064652 WO2017216281A1 (en) 2016-06-16 2017-06-15 Heterocyclic compounds as antibacterials

Publications (2)

Publication Number Publication Date
AU2017286368A1 AU2017286368A1 (en) 2018-12-06
AU2017286368B2 true AU2017286368B2 (en) 2021-02-25

Family

ID=56132837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017286368A Ceased AU2017286368B2 (en) 2016-06-16 2017-06-15 Heterocyclic compounds as antibacterials

Country Status (12)

Country Link
US (1) US11179396B2 (enExample)
EP (1) EP3472158A1 (enExample)
JP (1) JP2019518046A (enExample)
KR (1) KR20190017948A (enExample)
CN (1) CN109476657A (enExample)
AU (1) AU2017286368B2 (enExample)
BR (1) BR112018076126A2 (enExample)
CA (1) CA3026010A1 (enExample)
EA (1) EA201990043A1 (enExample)
MA (1) MA45377A (enExample)
MX (1) MX2018015656A (enExample)
WO (1) WO2017216281A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
CN114423758B (zh) 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
JP2022549881A (ja) * 2019-09-26 2022-11-29 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント, インコーポレイテッド マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用
KR20220071199A (ko) 2019-09-30 2022-05-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4-퀴놀리논 항균 화합물
CA3151712A1 (en) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3211592A1 (en) * 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) * 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509673A (pt) 1994-11-15 1997-09-30 Upjohn Co Compostos e uso dos mesmos
US6090820A (en) 1995-05-11 2000-07-18 Pharmacia & Upjohn Company Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones
SI1527050T1 (sl) 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CL2008001631A1 (es) 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
CN101965353B (zh) 2008-03-26 2014-12-17 丹诺医药(苏州)有限公司 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类
EP2353008A2 (en) 2008-09-22 2011-08-10 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
IN2012DN04917A (enExample) 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
WO2012143796A2 (en) 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6483610B2 (ja) * 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック 5,5−ヘテロ芳香族抗感染症化合物
WO2014023814A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
WO2015014993A2 (en) 2013-08-02 2015-02-05 Institut Pasteur Korea Anti-infective compounds
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
CN107249691A (zh) 2014-11-03 2017-10-13 加利福利亚大学董事会 用于肺结核治疗的多药疗法
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113606A1 (en) * 2010-03-18 2011-09-22 Institut Pasteur Korea Anti-infective compounds

Also Published As

Publication number Publication date
AU2017286368A1 (en) 2018-12-06
MX2018015656A (es) 2019-03-14
CN109476657A (zh) 2019-03-15
US20190134046A1 (en) 2019-05-09
EP3472158A1 (en) 2019-04-24
CA3026010A1 (en) 2017-12-21
US11179396B2 (en) 2021-11-23
MA45377A (fr) 2019-04-24
WO2017216281A1 (en) 2017-12-21
EA201990043A1 (ru) 2019-05-31
KR20190017948A (ko) 2019-02-20
BR112018076126A2 (pt) 2019-03-26
JP2019518046A (ja) 2019-06-27

Similar Documents

Publication Publication Date Title
AU2017286370B2 (en) Heterocyclic compounds as antibacte rials
AU2016287478B2 (en) Antibacterial compounds
US11179396B2 (en) Heterocyclic compounds as antibacterials
US20240199651A1 (en) Antibacterial compounds
OA19126A (en) Heterocyclic compounds as antibacterials
CA2986326C (en) Antibacterial compounds
OA19129A (en) Heterocyclic compounds as antibacterials.
HK40004907A (zh) 作为抗细菌剂的杂环化合物
OA19079A (en) Antibacterial compounds.
HK40004927A (zh) 杂环化合物作为抗细菌剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired